49 related articles for article (PubMed ID: 18949621)
1. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma.
Daniels-Wells TR; Candelaria PV; Kranz E; Wen J; Wang L; Kamata M; Almagro JC; Martínez-Maza O; Penichet ML
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980702
[TBL] [Abstract][Full Text] [Related]
3. Influence of Dehydroxymethylepoxyquinomicin on Radiosensitivity of Thyroid Carcinoma TPC-1 Cells.
Liu J; Cai H; Yi H; Li X; Peng Y; Li L
J Oncol; 2022; 2022():5026308. PubMed ID: 36213820
[TBL] [Abstract][Full Text] [Related]
4. The designed NF-κB inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases drug-sensitivity in mouse plasmacytoma SP2/0 cells.
Lin Y; Sidthipong K; Ma J; Koide N; Umezawa K; Kubota T
Exp Ther Med; 2021 Oct; 22(4):1092. PubMed ID: 34504546
[TBL] [Abstract][Full Text] [Related]
5. Role of nuclear factor-kappa B in feline injection site sarcoma.
Hsueh CS; Wu CH; Shih CH; Yeh JL; Jeng CR; Pang VF; Chiou HY; Chang HW
BMC Vet Res; 2019 Oct; 15(1):365. PubMed ID: 31653220
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib for the treatment of mantle cell lymphoma: an update.
Hambley B; Caimi PF; William BM
Ther Adv Hematol; 2016 Aug; 7(4):196-208. PubMed ID: 27493710
[TBL] [Abstract][Full Text] [Related]
7. P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.
Vega GG; Avilés-Salas A; Chalapud JR; Martinez-Paniagua M; Pelayo R; Mayani H; Hernandez-Pando R; Martinez-Maza O; Huerta-Yepez S; Bonavida B; Vega MI
BMC Cancer; 2015 Oct; 15():722. PubMed ID: 26475474
[TBL] [Abstract][Full Text] [Related]
8. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
Vega GG; Franco-Cea LA; Huerta-Yepez S; Mayani H; Morrison SL; Bonavida B; Vega MI
Int J Oncol; 2015 Nov; 47(5):1735-48. PubMed ID: 26398317
[TBL] [Abstract][Full Text] [Related]
9. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts.
Inokawa S; Watanabe T; Keino H; Sato Y; Hirakata A; Okada AA; Fukuda K; Fukushima A; Umezawa K
Graefes Arch Clin Exp Ophthalmol; 2015 Apr; 253(4):557-63. PubMed ID: 25519802
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bose P; Batalo MS; Holkova B; Grant S
Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation.
Rapino F; Naumann I; Fulda S
Cell Death Dis; 2013 Nov; 4(11):e925. PubMed ID: 24263099
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.
Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI
Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 monoclonal antibodies: historical and future perspectives.
Lim SH; Beers SA; French RR; Johnson PW; Glennie MJ; Cragg MS
Haematologica; 2010 Jan; 95(1):135-43. PubMed ID: 19773256
[TBL] [Abstract][Full Text] [Related]
15. The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Vega MI; Martinez-Paniagua M; Jazirehi AR; Huerta-Yepez S; Umezawa K; Martinez-Maza O; Bonavida B
Leuk Lymphoma; 2008 Oct; 49(10):1982-94. PubMed ID: 18949621
[TBL] [Abstract][Full Text] [Related]
16. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
[TBL] [Abstract][Full Text] [Related]
17. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
18. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
[TBL] [Abstract][Full Text] [Related]
19. What signals are generated by anti-CD20 antibody therapy?
Bonavida B
Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
